司库奇尤单抗治疗儿童中重度斑块状银屑病的疗效及安全性研究:附10例报告

Efficacy and safety of secukinumab for moderate to severe plaque psoriasis in children: A report of 10 cases

目的 探讨司库奇尤单抗治疗儿童中重度斑块状银屑病的疗效及安全性。方法 纳入2021年11月至2022年11月于永城市中心医院就诊且符合入组标准的10例中重度斑块状银屑病患儿,给予司库奇尤单抗皮下注射治疗,随访52周。记录患儿银屑病皮损面积和严重程度指数(PASI)、儿童皮肤病生活质量指数(CDLQI)变化,并观察不良反应情况。结果 治疗4周时,8例患者达到PASI 75,其中7例达到PASI 90,5例达到PASI 100;8周时,10例全部达到PASI 75,其中8例达到PASI 100;12周时,10例全部达到PASI 100;52周时,9例达到PASI 75,其中8例达到PASI 90,7例达到PASI 100。治疗4周时,所有患者CDLQI评分明显降低;52周时,CDLQI评分均降至0分。随访期间所有患儿未见相关不良反应。结论 司库奇尤单抗治疗儿童中重度斑块状银屑病起效快,疗效持久,能迅速改善患儿生活质量,且安全性高。

Objective To study the efficacy and safety of secukinumab in the treatment of moderate and severe plaque psoriasis in children.Methods A total of 10 children with psoriasis were enrolled at Yongcheng Central Hospital from November 2021 to November 2022.All patients were treated with subcutaneous injection of secukinumab and followed up for 52 weeks.The psoriasis area and severity index(PASI)and childrens′dermatology life quality index(CDLQI)were evaluated,and adverse reactions were observed.Results After 4 weeks of the treatment,8 patients achieved PASI 75,among which 7 patients achieved PASI 90 and PASI 100 was observed in 5 patients.After 8 weeks of the treatment,all 10 patients reached PASI 75,including 8 patients with PASI 100.After 12 weeks,all 10 patients achieved PASI 100.By 52 weeks,9 patients reached PASI 75,including 8 patients with PASI 90 and 7 patients with PASI 100.After 4 weeks of the treatment,CDLQI scores were significantly decreased and declined to 0 by 52 weeks.No adverse reactions were observed in all patients.Conclusions Secukinumab can rapidly improve moderate to severe plaque psoriasis in children and exhibits long-lasting benefit.It is safe and can quickly improve the quality of life of the children.